Form 4: Bolt Biotherapeutics Director Reprices Stock Options

Bolt Biotherapeutics director Laura Berner exchanged existing stock options for new options with lower exercise prices on December 12, 2025.

Summary

• Director Laura Berner engaged in a series of option exchanges on December 12, 2025.
• She cancelled existing stock options and received new options with a lower exercise price of $5.44 per share.
• The original options had exercise prices ranging from $6.40 to $32.60 per share.
• A total of 6,563 options were repriced.
• The repricing involved options originally granted on December 14, 2022, June 12, 2023, June 12, 2024, and May 27, 2025.
• The purpose of the exchange was to provide new options with a lower exercise price, likely due to the original options being underwater.

Sentiment

Score: 3

Explanation: The repricing of options, while potentially re-incentivizing the director, is generally a negative signal to the market, indicating significant past stock underperformance and potential shareholder dilution. It suggests the company's stock has fallen considerably, making previous grants ineffective.

Positives

• The repricing of options may re-incentivize the director by making the options 'in-the-money' or closer to it, potentially aligning their interests with future stock price appreciation.

Negatives

• Option repricing can be viewed negatively by shareholders as it dilutes existing shareholder value and effectively rewards management/directors despite poor stock performance.
• The significant reduction in exercise prices (e.g., from $32.60 to $5.44) suggests a substantial decline in the company's stock price since the original grant dates.

Risks

• Shareholder dissatisfaction due to perceived unfairness of repricing options when the stock price has declined.
• Potential for negative market reaction to the repricing, indicating past poor performance or lack of confidence in future recovery at previous price levels.
• The need for repricing itself suggests the company's stock has performed poorly, which is an underlying risk.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance beyond the vesting schedules and expiration dates of the options. The repricing itself implies a management belief in future stock price recovery from current low levels.

Industry Context

Option repricing is a common practice in industries where stock prices can be volatile, such as biotechnology, especially when a company's stock has significantly underperformed. It's a mechanism to retain and incentivize key personnel when original grants are underwater.

Comparison to Industry Standards

• Option repricing is a controversial practice. While it can re-incentivize employees/directors, it often faces criticism from institutional investors and proxy advisory firms (e.g., ISS, Glass Lewis) who generally view it as poor corporate governance, especially without shareholder approval or a value-for-value exchange.
• Companies like Biogen or Gilead Sciences have faced similar situations where stock performance led to underwater options, and their approaches to re-incentivization (e.g., new grants, repricing, or performance-based awards) are often scrutinized.
• The significant reduction in exercise price (e.g., from $32.60 to $5.44) suggests a substantial decline in Bolt Biotherapeutics' stock value, which is a more severe repricing than typically seen in stable industries.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential negative impact due to perceived dilution and rewarding underperformance. May raise questions about management accountability and corporate governance.
• Director (Laura Berner): Positive impact as her options are now more likely to be 'in-the-money' or closer to it, restoring incentive value.
• Employees: Could set a precedent for future option repricings for other employees, potentially boosting morale if their options are also underwater, but also signaling poor stock performance.

Next Steps

• The new options will vest according to their respective schedules, with some fully vested and others vesting over time or upon a change in control.
• The director will continue to hold these options, which become exercisable as they vest.

Key Dates

Recommendation

The repricing of options, especially with such a drastic reduction in exercise price, is a strong indicator of significant past stock underperformance. While it aims to re-incentivize the director, it signals a lack of confidence in the stock's ability to recover to previous levels and can be viewed negatively by the market as shareholder value dilution. This action suggests underlying issues with the company's performance or market perception, warranting a cautious or negative outlook.

Keywords

Bolt Biotherapeutics, BOLT, SEC Form 4, Stock Options, Option Repricing, Director Compensation, Insider Transaction, Equity Compensation, Corporate Governance